Q-omics provides the consensus-scored MIR503HG profile across patient tissues and cancer cell-line models. MIR503HG expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR503HG is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, MIR503HG RNA expression shows 17,767 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where MIR503HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR503HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR503HG survival associations across molecular data types. MIR503HG RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR503HG RNA expression–survival associations across cancer types. High MIR503HG expression shows unfavorable associations in ACC, UVM, MESO and KIRC, but favorable associations in THCA and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR503HG RNA expression.
This table summarizes MIR503HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR503HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR503HG shows lower tumor expression in KIRP, UCEC and KICH and higher tumor expression in HNSC, COAD and LUAD. The HNSC box plot shows higher MIR503HG RNA expression in tumor versus normal tissue (log2 FC = +1.794, t-test p < 0.001).
This table shows molecular features associated with MIR503HG in patient tissues and cancer cell lines. In patient samples, MIR503HG shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
